True North Therapeutics Appoints Pamela M. Wapnick As Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--True North Therapeutics, a clinical stage biopharmaceutical company developing novel product candidates that selectively inhibit the Complement system to treat certain rare diseases, announced the appointment of Pamela M. Wapnick as Chief Financial Officer (CFO). Ms. Wapnick brings more than 25 years of international business and finance experience to True North, most recently as Vice President of Finance at Amgen Corporation.

“Her breadth of experience in corporate finance and treasury within the biotechnology industry, including nearly 10 years at Amgen, will serve us well as we continue to advance True North’s pipeline of novel product candidates intended to selectively inhibit the Complement system to treat certain rare diseases with unmet need.”

“I am pleased to announce Pam’s appointment to the position of CFO as a member of our management team,” said Nancy Stagliano, PhD, Chief Executive Officer of True North. “Her breadth of experience in corporate finance and treasury within the biotechnology industry, including nearly 10 years at Amgen, will serve us well as we continue to advance True North’s pipeline of novel product candidates intended to selectively inhibit the Complement system to treat certain rare diseases with unmet need.”

“True North has rapidly established itself as a leader in the field of Complement system biology with its novel approach to treating Complement-mediated diseases,” said Pamela M. Wapnick. “This is an exciting time to join the True North team as the company plans to advance our lead drug candidate, TNT009, in clinical development and enter the next stage of building our financial, operations and R&D capabilities for the future.”

Ms. Wapnick joins True North Therapeutics from Amgen Corporation where she held senior financial management roles from 2007 to 2016, including Vice President of Finance for Research and Development, where she had corporate finance responsibility for Amgen’s global R&D activities, and Vice President and Treasurer of Amgen, where she had responsibility for global capital planning, capital markets and banking activities. Prior to Amgen, she held senior financial management positions in the automotive industry, including Federal Mogul Corporation, Delphi Corporation, and General Motors Corporation. Ms. Wapnick holds a bachelor’s degree in economics from Wellesley College and an MBA in finance from Columbia Business School.

About True North Therapeutics

True North Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class product candidates for Complement-mediated diseases. The company’s lead product candidate, TNT009, is designed to selectively inhibit a target in the Classical Complement pathway. True North’s antibody drug development is focused on the treatment of certain rare diseases mediated by the Complement system in hematology, transplantation, and dermatology. True North Therapeutics is located in South San Francisco, California. For more information, please visit www.truenorthrx.com.